Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 83.73% | 68.97% | 57.36% | 41.29% | 26.21% |
| Total Depreciation and Amortization | -70.69% | -35.34% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,155.35% | -275.34% | -71.17% | -73.21% | -75.37% |
| Change in Net Operating Assets | -96.55% | -22.10% | 161.86% | 82.74% | 38.42% |
| Cash from Operations | 55.93% | 64.71% | 71.00% | 50.34% | 30.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -48.36% | 6.78% | 6.78% | 6.78% |
| Total Debt Repaid | -- | -118.48% | -155.69% | -155.69% | -- |
| Issuance of Common Stock | -- | -6.76% | -81.09% | -91.66% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -109.84% | -- | -- | -- |
| Cash from Financing | 208.46% | -49.11% | -79.58% | -85.73% | -90.61% |
| Foreign Exchange rate Adjustments | -- | 150.00% | 150.00% | 150.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.53% | 95.73% | -469.72% | -339.87% | -328.90% |